Innogenetics on its Own
Executive Summary
Innogenetics, like many biotech companies, has built a diagnostics business in order to capture short-term revenues. But it got squeezed by industry consolidation and its response is an aggressive and expensive strategy to increase its emphasis on high-margin, novel tests, which it will use to fund conversion to a direct sales and marketing network in major markets.